News
10-05-2010, 05:50 AM
Enzon Pharmaceuticals, Inc. today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company's novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.
More... (http://www.news-medical.net/news/20101005/Preclinical-data-of-Enzons-PEG-SN38-in-pediatric-neuroblastoma-published-in-Clinical-Cancer-Research.aspx)
More... (http://www.news-medical.net/news/20101005/Preclinical-data-of-Enzons-PEG-SN38-in-pediatric-neuroblastoma-published-in-Clinical-Cancer-Research.aspx)